Biotech Values

[iwfal]

Presumably simultaneous targets at a given step of a 'preferred' sequence (e.g. within the adaptive category) could still work and possibly be more efficacious vs. simultaneous targets that occur at different steps of a preferred sequence (e.g. adaptive vs. innate).

Even within adaptive there are clearly optimal sequences (e.g. Vaccine booster timing), but equally clearly we understand it less than we do innate vs adaptive.

As for bispecifics that target two different checkpoints, I think some will have synergy. Just meaningfully suboptimal. And FWIW the n-specific targets that most interest me are the ones XNCR talked about - targeting regulatory T cells for destruction.